RE:RE:RE:RE:Rapid diagnosis It's a very long desert crossing. What next... another missed Q, a lowered revenue guidance and another giveway at 1$ for lack of closing a lifesaver deal to avoid the never ending ongoing concern. Nothing to go on apart free willy Linkedin testimonials and nash and onco roadshows that only yield lower stock price the next day. Normalicy would want attendees that are amazed by Thera's accomplishment to buy a couple of shares. Same goes for insiders. Nothing.